KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Depreciation and Depletion: 2015-2024

Historic Depreciation and Depletion for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Dec 2024 value amounting to $19.2 million.

  • CRISPR Therapeutics AG's Depreciation and Depletion fell 8.33% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.5 million, marking a year-over-year decrease of 4.15%. This contributed to the annual value of $19.2 million for FY2024, which is 3.03% down from last year.
  • CRISPR Therapeutics AG's Depreciation and Depletion amounted to $19.2 million in FY2024, which was down 3.03% from $19.8 million recorded in FY2023.
  • In the past 5 years, CRISPR Therapeutics AG's Depreciation and Depletion ranged from a high of $24.1 million in FY2022 and a low of $9.1 million during FY2020.
  • Moreover, its 3-year median value for Depreciation and Depletion was $19.8 million (2023), whereas its average is $21.0 million.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first spiked by 96.70% in 2021, then dropped by 17.84% in 2023.
  • CRISPR Therapeutics AG's Depreciation and Depletion (Yearly) stood at $9.1 million in 2020, then skyrocketed by 96.70% to $17.9 million in 2021, then skyrocketed by 34.64% to $24.1 million in 2022, then dropped by 17.84% to $19.8 million in 2023, then dropped by 3.03% to $19.2 million in 2024.